Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Foot Ankle Int ; 45(8): 905-915, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-38676564

RESUMEN

BACKGROUND: Diabetic foot ulcers (DFUs) constitute a complication that occurs in 19% to 34% of patients with diabetes mellitus (DM). The aim of this study is to describe median days to healing, average velocity of wound closure, and percentage of wound surface closed at 3, 6, and 12 weeks through the use of homogenized and lyophilized amniotic membrane (hAMpe) dressings for the treatment of DFUs in ambulatory patients. METHODS: An observational, descriptive, longitudinal study was performed. Patients presenting with granulation-based DFU, after proper debridement, were included from August 19, 2021, until July 14, 2023. hAMpe dressings placed every 3 days were used for the treatment of these ulcers. RESULTS: Sixteen patients were included with a mean age of 52.38 (8.07) years. The analyzed lesions were postsurgical ulcers in 15 of the 16 included patients. Median ulcer size was 19.5 cm2 (6.12-36). The median ABI was 1.10 (1-1.14). The median days to healing was 96 (71-170). The median percentage closure of the wound at 3 weeks was 41% (28.9%-55.3%), at 6 weeks it was 68.2% (48.6%-74.2%), and at 12 weeks it was 100% (81%-100%). The average velocity closure was 1.04% per day (95% CI 0.71%-1.31%). It was higher during the closure of the first 50% of the ulcer, 2.12% per day (95% CI 0.16%-4.09%), and decreased from 50% to 25% of the ulcer size to 0.67% per day (95% CI 0.23%-1.10%) and from 25% to closure to 0.47% per day (95% CI 0.14%-0.80%), P < .001. CONCLUSION: These results are difficult to compare to other studies given the higher surface area of the ulcers included in our sample. The development of hAMpe dressings enables patients to apply them without requiring assistance from health care teams and was not associated with any recognized complications.


Asunto(s)
Amnios , Pie Diabético , Cicatrización de Heridas , Humanos , Pie Diabético/terapia , Persona de Mediana Edad , Femenino , Masculino , Amnios/trasplante , Estudios Longitudinales , Apósitos Biológicos , Adulto , Liofilización , Vendajes , Anciano
2.
Heliyon ; 9(10): e20148, 2023 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-37822633

RESUMEN

HRSV is responsible for many acute lower airway infections and hospitalizations in infants, the elderly and those with weakened immune systems around the world. The strong inflammatory response that mediates viral clearance contributes to pathogenesis, and is positively correlated with disease severity. There is no specific effective therapy on hand. Antiviral synthetic stigmastanes (22S, 23S)-22,23-dihydroxystigmast-4-en-3-one (Compound 1) and 22,23-dihydroxystigmasta-1,4-dien-3-one (Compound 2) have shown to be active inhibiting unrelated virus like Herpes Simplex type 1 virus (HSV-1) and Adenovirus, without cytotoxicity. We have also shown that Compound 1 modulates the activation of cell signaling pathways and cytokine secretion in infected epithelial cells as well as in inflammatory cells activated by nonviral stimuli. In the present work, we investigated the inhibitory effect of both compounds on HRSV replication and their modulatory effect on infected epithelial and inflammatory cells. We show that compounds 1 and 2 inhibit in vitro HRSV replication and propagation and reduce cytokine secretion triggered by HRSV infection in epithelial and inflammatory cells. The compounds reduce viral loads and inflammatory infiltration in the lungs of mice infected with HRSV.

3.
J Pharm Pharmacol ; 70(11): 1561-1571, 2018 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-30168142

RESUMEN

OBJECTIVES: ß-Escin, one of the constituents of Aesculus hippocastanum L. (Hippocastanaceae) seed extract (AH), inhibits NF-κB activation, which plays an important role in HSV-1 replication. The aim was to examine the antiherpetic activity of ß-escin and AH, as well as their effect on the activation of NF-κB and AP-1 and cytokine secretion in epithelial cells and macrophages. METHODS: Cell viability was evaluated using MTT assay, and antiviral and virucidal activity was determined by plaque assay. The effect on NF-κB and AP-1 signalling pathways activation was determined by a luciferase reporter assay, and cytokine production was measured by ELISA. KEY FINDINGS: ß-Escin and AH had virucidal and anti-HSV-1 activities, and the antiviral activity was discovered for other enveloped viruses (VSV and Dengue). Moreover, ß-escin and AH significantly reduced NF-κB and AP-1 activation and cytokine production in macrophages stimulated with HSV-1 and TLRs ligands. However, an enhanced activation of these pathways and an increase in the levels of pro-inflammatory cytokines in ß-escin and AH-treated HSV-1-infected epithelial cells were found. CONCLUSIONS: This study demonstrates virucidal and broad-spectrum antiviral activities for ß escin and AH. Besides, ß-escin and AH modulate cytokine production depending on the stimuli (viral or non-viral) and the cell type under study.


Asunto(s)
Aesculus , Antivirales/farmacología , Células Epiteliales/efectos de los fármacos , Escina/farmacología , Factores Inmunológicos/farmacología , Macrófagos/efectos de los fármacos , Extractos Vegetales/farmacología , Virus/efectos de los fármacos , Células A549 , Aesculus/química , Animales , Antivirales/aislamiento & purificación , Citocinas/metabolismo , Virus del Dengue/efectos de los fármacos , Virus del Dengue/patogenicidad , Células Epiteliales/inmunología , Células Epiteliales/metabolismo , Células Epiteliales/virología , Escina/aislamiento & purificación , Herpesvirus Humano 1/efectos de los fármacos , Herpesvirus Humano 1/patogenicidad , Humanos , Factores Inmunológicos/aislamiento & purificación , Mediadores de Inflamación/metabolismo , Macrófagos/inmunología , Macrófagos/metabolismo , Macrófagos/virología , Ratones , FN-kappa B/metabolismo , Extractos Vegetales/aislamiento & purificación , Factor de Transcripción AP-1/metabolismo , Vesiculovirus/efectos de los fármacos , Vesiculovirus/patogenicidad , Virus/patogenicidad
4.
Biochim Biophys Acta ; 1860(1 Pt A): 129-39, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-26518349

RESUMEN

BACKGROUND: We have previously shown that some synthetic hydroxylated stigmastanes derived from plant sterols inhibit in vitro HSV-1 replication in ocular cell lines and decrease cytokine production in stimulated macrophages, suggesting that these steroids might combine antiviral and immunomodulating properties. In this paper we report the synthesis of some analogs fluorinated at C-6 in order to study the effect of this modification on bioactivity. METHODS: The following methods were used: organic synthesis of fluorinated analogs, cytotoxicity determination with MTT assays, cytokine production quantification with ELISAs, glucocorticoid activity determination by displacement assays, immunofluorescence and transcriptional activity assays, studies of the activation of signaling pathways by Western blot, antiviral activity evaluation through virus yield reduction assays. RESULTS: We report the chemical synthesis of new fluorinated stigmastanes and show that this family of steroidal compounds exerts its immunomodulating activity by inhibiting ERK and Akt signaling pathways, but do not act as glucocorticoids. We also demonstrate that fluorination enhances the antiviral activity. CONCLUSIONS: Fluorination on C-6 did not enhance the anti-inflammatory effect, however, an increase in the in vitro antiviral activity was observed. Thus, our results suggest that it is possible to introduce chemical modifications on the parent steroids in order to selectively modulate one of the effects. GENERAL SIGNIFICANCE: This family of steroids could allow the development of an alternative treatment for ocular immunopathologies triggered by HSV-1, without the undesirable side effects of the currently used drugs.


Asunto(s)
Antivirales/farmacología , Quinasas MAP Reguladas por Señal Extracelular/antagonistas & inhibidores , Herpesvirus Humano 1/efectos de los fármacos , Factores Inmunológicos/farmacología , Proteínas Proto-Oncogénicas c-akt/antagonistas & inhibidores , Receptores de Glucocorticoides/metabolismo , Transducción de Señal/efectos de los fármacos , Sitoesteroles/farmacología , Estigmasterol/farmacología , Animales , Chlorocebus aethiops , Citocinas/biosíntesis , Células HEK293 , Humanos , Macrófagos/efectos de los fármacos , Macrófagos/inmunología , Proteínas Proto-Oncogénicas c-akt/fisiología , Células Vero
5.
Med Microbiol Immunol ; 204(5): 575-84, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-25528328

RESUMEN

The pathogenesis of many viral infections lies on the damage caused by the immune response against the virus. Current antiviral drugs do not act on the inflammatory component of the disease. Thus, new compounds that inhibit both viral multiplication and the immunopathology elicited by the virus are an approach that should be considered. In the present study, we identified two jatropholones (2A and 5B) and one carnosic acid derivative (9C) that significantly inhibited multiplication of TK+ and TK- strains of HSV-1 in Vero cells. Compounds 2A, 5B and 9C also prevented HSV-1- and TLRs-induced inflammatory response in cultivated murine macrophages. In macrophages infected with HSV-1, the inhibitory effect of compounds 2A, 5B and 9C on TNF-α and IL-6 production could be associated with the block of ERK pathway, whereas NF-κB pathway was not hampered by any of the compounds. Besides, 2A, 5B and 9C also inhibited ERK pathway and reduced TNF-α production in macrophages stimulated with TLR2, TLR4 or TLR9 agonists and were able to hinder IL-6 secretion after activation with TLR2 or TLR4, but not with TLR9. The immunomodulatory effect of 2A, 5B and 9C in macrophages infected with HSV-1 may be a consequence of the inhibition of ERK pathway activated by TLRs. The availability of compounds with both antiviral and immunomodulatory properties which affect TLR signaling pathways might be a useful strategy to control the progress of virus-induced disease.


Asunto(s)
Antivirales/farmacología , Citocinas/antagonistas & inhibidores , Diterpenos/farmacología , Herpesvirus Humano 1/inmunología , Inmunosupresores/farmacología , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Replicación Viral , Animales , Línea Celular , Chlorocebus aethiops , Herpesvirus Humano 1/fisiología , Ratones
6.
Bioorg Med Chem ; 21(2): 560-8, 2013 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-23219855

RESUMEN

Many viral infections are associated with the development of immunopathologies and autoimmune diseases, which are of difficult treatment and for which no vaccines are yet available. Obtaining compounds that conjugate both antiviral and immunomodulatory activities in the same molecule would be very useful for the prevention and/or treatment of these immunopathologies. The compound (22S,23S)-22,23-dihydroxystigmast-4-en-3-one (compound 1) displays anti-Herpes simplex virus type 1 activity in vitro and reduces the incidence of herpetic stromal keratitis (HSK) in mice, a chronic inflammatory syndrome induced by ocular HSV-1 infection. In the present study, compound 1 showed opposite immunomodulatory properties in vitro. It induced the release of pro-inflammatory cytokines in HSV-1-infected epithelial cells of ocular origin, and significantly reduced the production of these cytokines in LPS-activated macrophages. RNA microarrays revealed various overexpressed and repressed genes in compound 1 treated infected epithelial cells and activated macrophages, many of which are associated with innate immune responses and inflammatory processes. These immunomodulatory properties of compound 1, together with its previously reported antiviral activity, make it a potential drug for the treatment of HSK and many other immunopathologies of viral and non-viral origin.


Asunto(s)
Antivirales/farmacología , Colestenonas/química , Herpesvirus Humano 1/efectos de los fármacos , Factores Inmunológicos/química , Estigmasterol/análogos & derivados , Animales , Antivirales/química , Antivirales/uso terapéutico , Línea Celular , Supervivencia Celular/efectos de los fármacos , Colestenonas/farmacología , Colestenonas/uso terapéutico , Sustancia Propia/citología , Sustancia Propia/virología , Citocinas/genética , Citocinas/metabolismo , Células Epiteliales/citología , Células Epiteliales/metabolismo , Células Epiteliales/virología , Perfilación de la Expresión Génica , Humanos , Factores Inmunológicos/farmacología , Factores Inmunológicos/uso terapéutico , Queratitis Herpética/tratamiento farmacológico , Queratitis Herpética/inmunología , Queratitis Herpética/veterinaria , Ratones , FN-kappa B/genética , FN-kappa B/metabolismo , Estigmasterol/química , Estigmasterol/farmacología , Estigmasterol/uso terapéutico , Activación Transcripcional/efectos de los fármacos
7.
J Steroid Biochem Mol Biol ; 111(1-2): 111-6, 2008 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-18619833

RESUMEN

Stromal keratitis resulting from ocular infection with Herpes simplex virus type 1 (HSV-1) is a common cause of blindness. This report investigates the antiviral and anti-inflammatory properties of two new synthetic stigmastane analogs in the experimental model of HSV-1-induced ocular disease in mice. (22S,23S)-22,23-dihydroxystigmast-4-en-3-one (1) and (22S,23S)-22,23-dihydroxystigmasta-1,4-dien-3-one (2) exhibited anti-HSV-1 activity in vitro and ameliorated the signs of murine herpetic stromal keratitis (HSK), although none of the compounds showed antiviral activity in vivo. We discuss that the improvement of HSK could be due to an immunomodulatory effect of both compounds.


Asunto(s)
Antiinflamatorios/farmacología , Antivirales/síntesis química , Antivirales/farmacología , Estigmasterol/análogos & derivados , Estigmasterol/síntesis química , Animales , Antivirales/química , Línea Celular , Supervivencia Celular/efectos de los fármacos , Chlorocebus aethiops , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Células Epiteliales/efectos de los fármacos , Células Epiteliales/metabolismo , Epitelio Corneal/efectos de los fármacos , Epitelio Corneal/metabolismo , Formazáns/metabolismo , Herpesvirus Humano 1/metabolismo , Humanos , Concentración 50 Inhibidora , Queratitis Herpética/tratamiento farmacológico , Masculino , Ratones , Ratones Endogámicos BALB C , Estructura Molecular , Espectrofotometría , Sales de Tetrazolio/metabolismo , Factores de Tiempo , Células Vero , beta-Galactosidasa/metabolismo
8.
J Steroid Biochem Mol Biol ; 108(1-2): 164-70, 2008 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-18054220

RESUMEN

Herpes simplex virus type 1 (HSV-1) induces an ocular chronic immunoinflammatory syndrome named herpetic stromal keratitis that can lead to vision impairment and blindness. We have reported that the synthetic brassinosteroid (22S,23S)-3beta-bromo-5alpha,22,23-trihydroxystigmastan-6-one, designated as 2, is a potent antiviral in vitro and reduces the incidence of murine herpetic stromal keratitis, although it does not exert an antiviral effect in vivo. In the present report, we investigated whether brassinosteroid 2 may play a role in the modulation of the response of epithelial and immune cells to HSV-1 infection. Compound 2 blocked HSV-1-induced activation of NF-kappaB by inhibiting its translocation to the nucleus of infected corneal and conjunctival cells in vitro, as well as significantly reduced the secretion of TNF-alpha in infected NHC cells. Conversely, IL-6 production was enhanced by compound 2 after HSV-1 infection in both cell types. The production of these cytokines was considerably reduced in a LPS-stimulated macrophage cell line after treatment with compound 2. In conclusion, brassinosteroid 2 would be playing a modulating effect as an inductor or inhibitor, depending on the cell type involved. The improvement of disease observed in mice could be a balance between both, the immunostimulating and immunosuppressive effects of brassinosteroid 2 in vivo.


Asunto(s)
Colestanonas/farmacología , Colestanonas/uso terapéutico , Queratitis Herpética/tratamiento farmacológico , Esteroides/farmacología , Esteroides/uso terapéutico , Animales , Antivirales/farmacología , Núcleo Celular/efectos de los fármacos , Núcleo Celular/metabolismo , Células Cultivadas , Células Epiteliales/efectos de los fármacos , Células Epiteliales/metabolismo , Epitelio Corneal/efectos de los fármacos , Epitelio Corneal/metabolismo , Regulación Viral de la Expresión Génica/efectos de los fármacos , Herpesvirus Humano 1/genética , Humanos , Factores Inmunológicos/farmacología , Interleucina-6/metabolismo , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Ratones , FN-kappa B/metabolismo , Factor de Necrosis Tumoral alfa/metabolismo , Proteínas del Envoltorio Viral/genética
9.
Bioorg Med Chem ; 15(24): 7538-44, 2007 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-17892941

RESUMEN

In a previous work our group showed that some synthetic stigmastanes may play a role in immune-mediated inflammation. In this paper we report the syntheses of a series of new steroidal compounds derived from dehydroepiandrosterone and stigmasterol, and the evaluation of their in vitro inhibitory activity of the TNF-alpha production by macrophages. A preliminary qualitative structure-activity relationship was established.


Asunto(s)
Androstanos/síntesis química , Androstanos/farmacología , Colestanos/síntesis química , Colestanos/farmacología , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Androstanos/química , Animales , Línea Celular , Colestanos/química , Deshidroepiandrosterona/química , Evaluación Preclínica de Medicamentos , Factores Inmunológicos/síntesis química , Factores Inmunológicos/química , Factores Inmunológicos/farmacología , Ratones , Estructura Molecular , Estigmasterol/química , Relación Estructura-Actividad
10.
Biochem Biophys Res Commun ; 344(3): 955-62, 2006 Jun 09.
Artículo en Inglés | MEDLINE | ID: mdl-16631615

RESUMEN

We have reported the isolation of the tetranortriterpenoid 1-cinnamoyl-3,11-dihydroxymeliacarpin (CDM) from partially purified leaf extracts of Melia azedarach L. (MA) that reduced both, vesicular stomatitis virus (VSV) and Herpes simplex virus type 1 (HSV-1) multiplication. CDM blocks VSV entry and the intracellular transport of VSV-G protein, confining it to the Golgi apparatus, by pre- or post-treatment, respectively. Here, we report that HSV-1 glycoproteins were also confined to the Golgi apparatus independently of the nature of the host cell. Considering that MA could be acting as an immunomodulator preventing the development of herpetic stromal keratitis in mice, we also examined an eventual effect of CDM on NF-kappaB signaling pathway. CDM is able to impede NF-kappaB activation in HSV-1-infected conjunctival cells and leads to the accumulation of p65 NF-kappaB subunit in the cytoplasm of uninfected treated Vero cells. In conclusion, CDM is a pleiotropic agent that not only inhibits the multiplication of DNA and RNA viruses by the same mechanism of action but also modulates the NF-kappaB signaling pathway.


Asunto(s)
Conjuntiva/virología , Herpesvirus Humano 1/efectos de los fármacos , Herpesvirus Humano 1/crecimiento & desarrollo , Limoninas/administración & dosificación , FN-kappa B/efectos de los fármacos , FN-kappa B/metabolismo , Replicación Viral/fisiología , Animales , Antivirales/administración & dosificación , Línea Celular , Chlorocebus aethiops , Conjuntiva/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Humanos , Células Vero , Replicación Viral/efectos de los fármacos
11.
Steroids ; 69(11-12): 713-20, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15579323

RESUMEN

Brassinosteroids are a novel group of steroids that appear to be ubiquitous in plants and are essential for normal plant growth and development. It has been previously reported that brassinosteroid analogues exert an antiviral activity against herpes simplex virus type 1 (HSV-1) and arenaviruses. In the present study, we report the chemical synthesis of compounds (22S,23S)-3beta-bromo-5alpha,22,23-trihydroxystigmastan-6-one (2), (22S,23S)-5alpha-fluoro-3beta-22,23-trihydroxystigmastan-6-one (3), (22S,23S)-3beta,5alpha,22,23-tetrahydroxy-stigmastan-6-one (4) as well as their antiherpetic activity both in a human conjunctive cell line (IOBA-NHC) and in the murine herpetic stromal keratitis (HSK) experimental model. All compounds prevented HSV-1 multiplication in NHC cells in a dose dependent manner when added after infection with no cytotoxicity. Administration of compounds 2, 3, and 4 to the eyes of mice at 1, 2, and 3 days post-infection delayed and reduced the incidence of HSK, consisting mainly of inflammation, vascularization, and necrosis, compared to untreated, infected mice. However, viral titers of eye washes showed no differences among samples from treated and untreated mice. Since the decrease in the percentage of mice with ocular lesions occurred 5 days after treatment had ended, we suggest that brassinosteroids 2, 3, and 4 did not exert a direct antiviral effect in vivo, but rather may play a role in immune-mediated stromal inflammation, which would explain the improvement of the clinical signs of HSK observed.


Asunto(s)
Antivirales/química , Antivirales/síntesis química , Antivirales/farmacología , Colestanonas/síntesis química , Estigmasterol/análogos & derivados , Estigmasterol/síntesis química , Animales , Antiinflamatorios/farmacología , Línea Celular , Supervivencia Celular , Chlorocebus aethiops , Relación Dosis-Respuesta a Droga , Herpesvirus Humano 1/metabolismo , Humanos , Inflamación , Masculino , Ratones , Ratones Endogámicos BALB C , Modelos Químicos , Espectrofotometría , Esteroides/síntesis química , Esteroides/química , Factores de Tiempo , Células Vero , beta-Galactosidasa/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA